novo nordisk glp-1 weight loss glp 1 pill BREAKING: The FDA has approved the first oral for obesity, marking a major milestone in the weight-loss drug market and 80% of Wegovy Pill Users

Before enrolling, youll receive detailed information through an informed consent process so you can weigh all the pros and cons of participating first

Another example entails the established cardioprotective activity of GLP-1RAs,111 perhaps together with other helpful actions on brain perfusion as seen in the Cerebrovascular system and BBB dynamics section,50 which may have direct relevance to controlling risk factors such as hypertension and atherosclerosis,112 hence to the prevention of non-fatal stroke events and ultimately VaD.13 GLP-1RAs are also being investigated for the treatment of addiction, with preliminary evidence suggesting that they might be useful for reducing smoking57 113 and alcohol misuse114important risk factors for AD, alcohol-related dementia and other cognitive impairments.115 The development of novel GLP-1RAs could therefore be integrated with lifestyle interventions directly impacting key determinants of health116 to improve brain health and healthy ageing.117 Adverse events and other unwanted effects Studies thus far have broadly reported that GLP-1RAs display a benign safety profile,6 including in terms of adverse neuropsychiatric outcomes.17 Gastrointestinal symptoms, including nausea, bloating and sometimes vomiting, are the most common side effects, generally occurring during the first few weeks of taking the medications and subsiding with prolonged administrations.6 Some controversy remains regarding the relationship between these drugs and suicidality.118 Within the context of CNS disorders, pharmaceutical companies and researchers should also consider the development of GLP-1 agents that do not cause weight loss, especially of lean muscle massa peripheral effect that would be undesirable in frail older adults

Each study seems to show that the next medication is at least as good as or better than the previous ones are

Lilly, E

Ready for Real Change

its relatively short half-life requires twice-daily administration [17]